These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

297 related articles for article (PubMed ID: 32007960)

  • 41. Genotype-phenotype correlation of SMN locus genes in spinal muscular atrophy children from Argentina.
    Medrano S; Monges S; Gravina LP; Alías L; Mozzoni J; Aráoz HV; Bernal S; Moresco A; Chertkoff L; Tizzano E
    Eur J Paediatr Neurol; 2016 Nov; 20(6):910-917. PubMed ID: 27510309
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Beyond type I spinal atrophy].
    Mastella C
    Assist Inferm Ric; 1999; 18(4):240-6. PubMed ID: 10833298
    [No Abstract]   [Full Text] [Related]  

  • 43. Correlation of SMN2, NAIP, p44, H4F5 and Occludin genes copy number with spinal muscular atrophy phenotype in Tunisian patients.
    Amara A; Adala L; Ben Charfeddine I; Mamaï O; Mili A; Lazreg TB; H'mida D; Amri F; Salem N; Boughammura L; Saad A; Gribaa M
    Eur J Paediatr Neurol; 2012 Mar; 16(2):167-74. PubMed ID: 21821450
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Spinal muscular atrophy due to double gene conversion event.
    Maamouri W; Hammer MB; Bouhlel Y; Souilem S; Khmiri N; Nehdi H; Hentati F; Amouri R
    Int J Neurosci; 2011 Feb; 121(2):107-11. PubMed ID: 21047176
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nusinersen in type 1 spinal muscular atrophy: Twelve-month real-world data.
    Pane M; Coratti G; Sansone VA; Messina S; Bruno C; Catteruccia M; Sframeli M; Albamonte E; Pedemonte M; D'Amico A; Bravetti C; Berti B; Brigati G; Tacchetti P; Salmin F; de Sanctis R; Lucibello S; Piastra M; Genovese O; Bertini E; Vita G; Tiziano FD; Mercuri E;
    Ann Neurol; 2019 Sep; 86(3):443-451. PubMed ID: 31228281
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Joint effect of the SMN2 and SERF1A genes on childhood-onset types of spinal muscular atrophy in Serbian patients.
    Brkušanin M; Kosać A; Jovanović V; Pešović J; Brajušković G; Dimitrijević N; Todorović S; Romac S; Milić Rašić V; Savić-Pavićević D
    J Hum Genet; 2015 Nov; 60(11):723-8. PubMed ID: 26311540
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Newborn Screening for Spinal Muscular Atrophy: DNA Preparation from Dried Blood Spot and DNA Polymerase Selection in PCR.
    Takeuchi A; Tode C; Nishino M; Wijaya YOS; Niba ETE; Awano H; Takeshima Y; Saito T; Saito K; Lai PS; Bouike Y; Nishio H; Shinohara M
    Kobe J Med Sci; 2019 Nov; 65(3):E95-E99. PubMed ID: 32029694
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care.
    Mercuri E; Finkel RS; Muntoni F; Wirth B; Montes J; Main M; Mazzone ES; Vitale M; Snyder B; Quijano-Roy S; Bertini E; Davis RH; Meyer OH; Simonds AK; Schroth MK; Graham RJ; Kirschner J; Iannaccone ST; Crawford TO; Woods S; Qian Y; Sejersen T;
    Neuromuscul Disord; 2018 Feb; 28(2):103-115. PubMed ID: 29290580
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Multiplex Droplet Digital PCR Method Applicable to Newborn Screening, Carrier Status, and Assessment of Spinal Muscular Atrophy.
    Vidal-Folch N; Gavrilov D; Raymond K; Rinaldo P; Tortorelli S; Matern D; Oglesbee D
    Clin Chem; 2018 Dec; 64(12):1753-1761. PubMed ID: 30352867
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Congenital heart disease is a feature of severe infantile spinal muscular atrophy.
    Rudnik-Schöneborn S; Heller R; Berg C; Betzler C; Grimm T; Eggermann T; Eggermann K; Wirth R; Wirth B; Zerres K
    J Med Genet; 2008 Oct; 45(10):635-8. PubMed ID: 18662980
    [TBL] [Abstract][Full Text] [Related]  

  • 51. SMA Diagnosis: Detection of SMN1 Deletion with Real-Time mCOP-PCR System Using Fresh Blood DNA.
    Niba ETE; Ar Rochmah M; Harahap NIF; Awano H; Morioka I; Iijima K; Saito T; Saito K; Takeuchi A; Lai PS; Bouike Y; Nishio H; Shinohara M
    Kobe J Med Sci; 2017 Dec; 63(3):E80-E83. PubMed ID: 29434179
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A paucisymptomatic neuromuscular disease mimicking type III 5q-SMA with complex rearrangements in the SMN gene.
    Lohkamp LN; von Au K; Goebel HH; Kress W; Grieben U; Drossel K; Garbes L; Wirth B; Heppner FL; Stenzel W
    J Child Neurol; 2014 Feb; 29(2):254-9. PubMed ID: 24334346
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Possible treatments for infantile spinal atrophy].
    Pascual-Pascual SI; Garcia-Romero M
    Rev Neurol; 2017 May; 64(s03):S19-S24. PubMed ID: 28524214
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative analyses of SMN1 and SMN2 based on real-time lightCycler PCR: fast and highly reliable carrier testing and prediction of severity of spinal muscular atrophy.
    Feldkötter M; Schwarzer V; Wirth R; Wienker TF; Wirth B
    Am J Hum Genet; 2002 Feb; 70(2):358-68. PubMed ID: 11791208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Type 0 Spinal Muscular Atrophy: Further Delineation of Prenatal and Postnatal Features in 16 Patients.
    Grotto S; Cuisset JM; Marret S; Drunat S; Faure P; Audebert-Bellanger S; Desguerre I; Flurin V; Grebille AG; Guerrot AM; Journel H; Morin G; Plessis G; Renolleau S; Roume J; Simon-Bouy B; Touraine R; Willems M; Frébourg T; Verspyck E; Saugier-Veber P
    J Neuromuscul Dis; 2016 Nov; 3(4):487-495. PubMed ID: 27911332
    [TBL] [Abstract][Full Text] [Related]  

  • 56. From Clinical Trials to Clinical Practice: Practical Considerations for Gene Replacement Therapy in SMA Type 1.
    Al-Zaidy SA; Mendell JR
    Pediatr Neurol; 2019 Nov; 100():3-11. PubMed ID: 31371124
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Incidence of infantile spinal muscular atrophy on Shikoku Island of Japan.
    Okamoto K; Fukuda M; Saito I; Urate R; Maniwa S; Usui D; Motoki T; Jogamoto T; Aibara K; Hosokawa T; Konishi Y; Arakawa R; Mori K; Ishii E; Saito K; Nishio H
    Brain Dev; 2019 Jan; 41(1):36-42. PubMed ID: 30093179
    [TBL] [Abstract][Full Text] [Related]  

  • 58. A preliminary report on spinal muscular atrophy lymphoblastoid cell lines: are they an appropriate tool for drug screening?
    Dayangaç-Erden D; Topaloğlu H; Erdem-Yurter H
    Adv Ther; 2008 Mar; 25(3):274-9. PubMed ID: 18345520
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular mechanisms of spinal muscular atrophy.
    Sumner CJ
    J Child Neurol; 2007 Aug; 22(8):979-89. PubMed ID: 17761653
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Valproic acid increases SMN levels in spinal muscular atrophy patient cells.
    Sumner CJ; Huynh TN; Markowitz JA; Perhac JS; Hill B; Coovert DD; Schussler K; Chen X; Jarecki J; Burghes AH; Taylor JP; Fischbeck KH
    Ann Neurol; 2003 Nov; 54(5):647-54. PubMed ID: 14595654
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.